Although not significant in all studies, post-hoc analysis of the placebo-controlled studies in phase III showed that DPP-4 inhibitors slightly lower blood pressure, improve post-prandial and fasting lipemia, reduce inflammatory markers, diminish oxidative stress, improve endothelial function, and reduce platelet aggregation in type 2 diabetes (122). Here, DPP4 is linked to type 2 diabetes mellitus.